Peer-reviewedCC BY-NC-NDRevue médicale suisse
Neurology : what's new in 2025
Abstract
In 2025, several major advances have marked the field of neurology. Anti-FcRN and anti-C5 antibodies have confirmed their long-term efficacy in the treatment of myasthenia gravis. Bruton tyrosine kinase inhibitors have expanded the therapeutic arsenal for multiple sclerosis. An antibody targeting α-synuclein appears to slow motor decline in early-stage Parkinson's disease. The efficacy of late thrombolysis in strokes with radiological mismatch has been confirmed. A blood biomarker facilitates early detection of Alzheimer's disease, and Swiss guidelines specify the modality for the use of anti-amyloid therapies in this disease. Finally, in pregnant women with epilepsy, the recommended dose of folic acid has been reduced.
Related
- Neurology Wait Times in the Cognitive Care Journey
- The Neurology Workforce in American Medicine
- Harnessing Artificial Intelligence and ChatGPT in Early Detection of Neurodegenerative Disorders: A Transformative Opportunity for Neurology
- Menopause and Neurology
- Evaluation of methodology, reporting and transparency of 50 highly cited randomised trials in neurology: a cross-sectional analysis
BibTeX
@article{tziakouri2026neurology,
title = {{Neurology : what's new in 2025}},
author = {Andria Tziakouri and Valentin Loser and Alex Vicino and Thomas Baumgartner and Giovanni Di Liberto and Vasiliki Pantazou and Raphaël Bernard-Valnet and Marie Theaudin and Caroline Pot and Mayte Castro-Jimenez and Cecile Alexandra Hübsch and Julien Bally and Davide Strambo and Lorenz Hirt and Leonardo Caranzano and Olivier Rouaud and Gilles Allali and Paolo Salvioni and Arseny Sokolov and Jean-Michel Pignat and Philippe Ryvlin and Matthieu Perrenoud and Andrea Rossetti and Jan Novy and Isabelle Beuchat and Renaud Du Pasquier and Patrik Michel},
journal = {Revue médicale suisse},
year = {2026},
month = oct,
doi = {10.53738/revmed.2026.22.946.48114},
url = {https://hal.science/hal-05795903v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Neurology : what's new in 2025
AU - Andria Tziakouri
AU - Valentin Loser
AU - Alex Vicino
AU - Thomas Baumgartner
AU - Giovanni Di Liberto
AU - Vasiliki Pantazou
AU - Raphaël Bernard-Valnet
AU - Marie Theaudin
AU - Caroline Pot
AU - Mayte Castro-Jimenez
AU - Cecile Alexandra Hübsch
AU - Julien Bally
AU - Davide Strambo
AU - Lorenz Hirt
AU - Leonardo Caranzano
AU - Olivier Rouaud
AU - Gilles Allali
AU - Paolo Salvioni
AU - Arseny Sokolov
AU - Jean-Michel Pignat
AU - Philippe Ryvlin
AU - Matthieu Perrenoud
AU - Andrea Rossetti
AU - Jan Novy
AU - Isabelle Beuchat
AU - Renaud Du Pasquier
AU - Patrik Michel
PY - 2026
DA - 2026/10/12
JO - Revue médicale suisse
DO - 10.53738/revmed.2026.22.946.48114
UR - https://hal.science/hal-05795903v1
AB - In 2025, several major advances have marked the field of neurology. Anti-FcRN and anti-C5 antibodies have confirmed their long-term efficacy in the treatment of myasthenia gravis. Bruton tyrosine kinase inhibitors have expanded the therapeutic arsenal for multiple sclerosis. An antibody targeting α-synuclein appears to slow motor decline in early-stage Parkinson's disease. The efficacy of late thrombolysis in strokes with radiological mismatch has been confirmed. A blood biomarker facilitates early detection of Alzheimer's disease, and Swiss guidelines specify the modality for the use of anti-amyloid therapies in this disease. Finally, in pregnant women with epilepsy, the recommended dose of folic acid has been reduced.
SN - 1660-9379
SN - 3042-6782
ER -